Adams, Craig

Donnelly, Catherine

Macdonald, Angus Smith

English

Genetic studies indicate that the inherited risk of breast cancer is mediated by the well-studied major genes BRCA1 and BRCA2, and a polygenic component, probably with many genes each making a small contribution. Recently, seven polygenes have been found (Pharoah et al., 2008) contributing an estimated 3.6% of all familial risk (Easton et al., 2007) This suggests that the polygenic component may involve well over 100 genetic loci.We extrapolate these new results into a polygenic model with 147 genetic loci and simulate lifetimes of families to calculate the premium ratings appropriate for a family history of breast or ovarian cancer. We model the adverse selection costs arising from restricting the use of genetic test information in critical illness insurance underwriting in light of new European legislation banning the use of gender for insurance underwriting. In this setting we conrm the overall conclusion of Macdonald &amp; McIvor (2009) that the polygene confers higher adverse selection risk than the BRCA genes. We establish that their three-gene polygenic model does not overly inflate the insurance costs attributable to a polygenic component of breast cancer risk under a model with 147 polygenes

Heriot Watt Pure

The impact of known breast cancer polygenes on critical illness insurance

A common coding variant in CASP8 is associated with breast cancer risk.

A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.

A genome-wide association study identi alleles in fgfr2 associated with risk of sporadic postmenopausal breast cancer.

Adult polycystic kidney disease and critical illness insurance.

An approximate model of polygenic inheritance.

Application of a polygenic model of breast and ovarian cancer to critical illness insurance.

Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.

Cancer burden in the year 2000. the global picture.

Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer.

Estimating adverse selection costs from genetic testing for breast and ovarian cancer: The case of life insurance.

Evidence for further breast caner susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.

Evidence of adverse selection in the individual health insurance market.

Genetic testing, adverse selection, and the demand for life insurance.

Genome-wide association analysis identi three new breast cancer susceptibility loci.

Genome-wide association study identi novel breast cancer susceptibility loci.

Modelling adverse selection in the presence of a common genetic disorder: The breast cancer polygene.

Multiple dimensions of private information: evidence from the longterm care insurance market.

Polygenes, risk prediction, and targeted prevention of breast cancer.

Pricing term insurance in the presence of a family history of breast or ovarian cancer.

Rapid progression of prostate cancer in men with a BRCA2 mutation.

Risk factors and epidemiology of breast cancer.

Selection eects in the United Kingdom individual annuities market.

The genetics of breast and ovarian cancer I: a model of family history.

The genetics of breast and ovarian cancer II: a model of critical illness insurance.

The genetics of breast and ovarian cancer III: a new model of family history with insurance applications.

The genetics of breast and ovarian cancer IV: A model of breast cancer progression.

The genetics of breast and ovarian cancer V: Application to income protection insurance.

The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.

The impact of known breast cancer polygenes on critical illness insurance

Abstract

Similar works

Full text

Available Versions

Heriot Watt Pure

Heriot Watt Pure